Immunic, Inc.
IMUX
Rank in Stocks
#19359
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development... Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORฮณt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
Share Price
$7.96
Last synced: 2026-11-09
Market Cap
$108.61M
Change (1 day)
2.71%
Change (1 year)
4.74%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Immunic, Inc. (IMUX)
Category
Healthcare
EPS for Immunic, Inc. (IMUX)
EPS as of June 2026 TTM: $-4.80
According to Immunic, Inc.'s latest financial reports, its current EPS (TTM) is $-4.80. At the end of 2025 the company had an EPS of $-6.24, an increase over its 2024 EPS of $-10.03.
EPS history for Immunic, Inc. from 2011 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-4.80 | -23.08% |
| 2025 | $-6.24 | -37.79% |
| 2024 | $-10.03 | -52.51% |
| 2023 | $-21.12 | -44.19% |
| 2022 | $-37.84 | -3.72% |
| 2021 | $-39.30 | 39.86% |
| 2020 | $-28.10 | -37.89% |
| 2019 | $-45.24 | -66.80% |
| 2018 | $-136.28 | -73.99% |
| 2017 | $-524.00 | 0.00% |
| 2016 | $-524.00 | -36.71% |
| 2015 | $-828.00 | -41.53% |
| 2014 | $-1.42K | 168.11% |
| 2013 | $-528.14 | 311.00% |
| 2012 | $-128.50 | 19.10% |
| 2011 | $-107.89 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -426.25% |
US
|
|
| $-7.07 | 47.29% |
US
|
|
| $-5.29 | 10.21% |
AU
|
|
| $12.88 | -368.34% |
BE
|
|
| $21.56 | -549.17% |
NL
|
Questions about Immunic, Inc.'s earnings per share (EPS)
What is Immunic, Inc.'s earnings per share (EPS)?
Immunic, Inc.'s earnings per share (EPS) over the last twelve months is $-4.80, as of Jun 2026.
What was Immunic, Inc.'s earnings per share (EPS) in 2025?
In 2025, Immunic, Inc.'s earnings per share (EPS) was $-6.24, compared with $-10.03 in 2024.
How has Immunic, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Immunic, Inc.'s earnings per share (EPS) was highest in 2025 ($-6.24) and lowest in 2021 ($-39.30).
How does Immunic, Inc.'s earnings per share (EPS) compare with similar companies?
Immunic, Inc.'s earnings per share (EPS) ($-4.80) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.